top
Search terms
Results 1 - 10 of 11 - ordered by :
Pages: 1 2
Epeuropace

Introduction Chagas' disease is a major cause of morbidity and mortality in Latin America,1 and has become a worldwide problem due to growing immigration from endemic areas.2,3 Chagas' heart disease ...

Europace, Sudden death and ICDs, Wagner L. Gali, Alvaro V. Sarabanda, José M. Baggio, Luís G. Ferreira, Gustavo G. Gomes, J. Antônio Marin-Neto, Luiz F. Junqueira

Date : 01/05/2014 Item size : 234733 bytes
Epeuropace

Introduction Implantable cardioverter-defibrillator (ICD) therapy improves survival in patients at high sudden cardiac death (SCD) risk.1 However, subpopulations of implanted patients do not derive ...

Europace, CLINICAL RESEARCH, Paul A. Scott, Paul A. Townsend, Leong L. Ng, Mehmood Zeb, Scott Harris, Paul J. Roderick, Nick P. Curzen, John M. Morgan

Date : 01/10/2011 Item size : 237496 bytes
Epeuropace

Mortality and morbidity in cardiac resynchronization patients: impact of lead position, paced left ventricular QRS morphology and other characteristics on long-term outcome Abstract Aims To ...

Europace, CLINICAL RESEARCH, Marek Jastrzebski, Jerzy Wiliński, Kamil Fijorek, Tomasz Sondej, Danuta Czarnecka

Date : 01/02/2013 Item size : 265981 bytes
Epeuropace

Methods and results The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a randomized, double-blind controlled trial that recruited 5804 individuals aged 7082 years with a ...

Europace, Atrial Fibrillation, Peter W. Macfarlane, Heather Murray, Naveed Sattar, David J. Stott, Ian Ford, Brendan Buckley, J. Wouter Jukema, Rudi G.J. Westendorp, James Shepherd

Date : 01/05/2011 Item size : 229229 bytes
Epeuropace

Predictors of mortality included a history of atrial fibrillation (AF, P < 0.0001), diabetes (P = 0.0001), failure to use cholesterol-lowering medications (P < 0.001), use of digitalis and ...

Europace, Kenneth M. Stein, Suneet Mittal, F. Roosevelt Gilliam, David M. Gilligan, Qian Zhong, Stacia Merkel Kraus, Timothy E. Meyer

Date : 01/06/2009
Epeuropace

The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality Abstract Aims Comorbidity, such as myocardial ...

Europace, CLINICAL RESEARCH, Dominic A.M.J. Theuns, Beat A. Schaer, Osama I.I. Soliman, David Altmann, Christian Sticherling, Marcel L. Geleijnse, Stefan Osswald, Luc Jordaens

Date : 01/01/2011
Epeuropace

After multivariable adjustment, lung disease [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.291.66], diabetes [1.22, (1.111.34)], prior MI [1.27, (1.131.42)], and renal dysfunction [HR 1.07 ...

Europace, CLINICAL RESEARCH, Adam D. DeVore, Anne S. Hellkamp, Richard C. Becker, Scott D. Berkowitz, Guenter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, ...

Date : 01/08/2016
Epeuropace

Abstract Aims Given the selectivity of clinical trial patients and meager representation of elderly in the major implantable cardioverter defibrillator (ICD) randomized trials (<25%), whether such ...

Europace, CLINICAL RESEARCH, Cara N. Pellegrini, Keane Lee, Jeffrey E. Olgin, Mintu P. Turakhia, Zian H. Tseng, Randall Lee, Nitish Badhwar, Byron Lee, Paul D. Varosy

Date : 01/11/2008
Epeuropace

[...]previous studies113 have shown that 2043% of all MIs are not diagnosedeither because there are no symptoms (silent MI) or because the symptoms are so mild or diffuse that neither patient nor ...

Europace, CLINICAL RESEARCH, Peter Godsk, Jan Skov Jensen, Steen Z. Abildstrøm, Merete Appleyard, Sune Pedersen, Rasmus Mogelvang

Date : 01/07/2012
Epeuropace

Abstract Aims Cardiac resynchronization therapy (CRT) has been proven to be effective in patients suffering from chronic heart failure (CHF) associated with electrical dyssynchrony. Patients with ...

Europace, María Ángeles Castel, Francisco Méndez, David Tamborero, Lluís Mont, Santiago Magnani, Jose Maria Tolosana, Antonio Berruezo, Miguel Godoy, Marta Sitges, Barbara Vidal, ...

Date : 01/03/2009